Cargando…

Outcomes in refractory diffuse large B‐cell lymphoma: results from a multicenter real‐world study in China

BACKGROUND: Diffuse large B‐cell lymphoma (DLBCL) patients refractory to rituximab‐based immunochemotherapy have a dismal prognosis. However, the definition of refractory DLBCL remains inconsistent and no large cohort study data is available from Asian countries. To validate the definition and outco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Shuo, Wang, Li, Hu, Jianda, Qian, Wenbin, Zhang, Xi, Hu, Yu, Zhu, Qi, Chen, Bobin, Wu, Depei, Chang, Chung‐Chou H., Xu, Pengpeng, Zheng, Xiaoyun, Wei, Juying, Liu, Yao, Cui, Guohui, Tang, Yong, Ma, Yan, Huang, Haiwen, Yi, Hongmei, Zhao, Weili
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7968882/ https://www.ncbi.nlm.nih.gov/pubmed/33482051 http://dx.doi.org/10.1002/cac2.12126

Ejemplares similares

Initial Treatment Patterns and Survival Outcomes of Mantle Cell Lymphoma Patients Managed at Chinese Academic Centers in the Rituximab Era: A Real-World Study
por: Wu, Meng, et al.
Publicado: (2022)

Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide
por: Cheng, Lili, et al.
Publicado: (2021)

Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study
por: Xu, Wei, et al.
Publicado: (2020)

Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
por: Shi, Yuankai, et al.
Publicado: (2017)

P1203: EFFICACY AND SAFETY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) FOR THE TREATMENT OF RELAPSE/REFRACTORY NON-HODGKIN LYMPHOMA: FIRST REAL-WORLD DATA IN CHINESE POPULATION
por: Wang, LI, et al.
Publicado: (2023)

Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma
por: Song, Yuqin, et al.
Publicado: (2023)

Molecular Heterogeneity in Localized Diffuse Large B-Cell Lymphoma
por: Qin, Wei, et al.
Publicado: (2021)

Integrated Genomic and Transcriptomic Analyses of Diffuse Large B-Cell Lymphoma With Multiple Abnormal Immunologic Markers
por: Sheng, Lingshuang, et al.
Publicado: (2022)

Radiotherapy or chemotherapy: a real-world study of the first-time relapsed and refractory primary central nervous system lymphoma
por: Yang, Yu, et al.
Publicado: (2023)

Etoposide, dexamethasone, and pegaspargase with sandwiched radiotherapy in early-stage natural killer/T-cell lymphoma: A randomized phase III study
por: Zhong, Huijuan, et al.
Publicado: (2023)

Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma
por: Zhu, Yue, et al.
Publicado: (2022)

Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
por: Yuan, Xianggui, et al.
Publicado: (2022)

A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China
por: Liu, Weiping, et al.
Publicado: (2021)

Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients
por: Qu, Changju, et al.
Publicado: (2022)

Sustained Remission of Relapsed or Refractory Mantle Cell Lymphoma After 4-1BB-Based CD19-Directed CAR-T Therapy
por: Yang, Chunmei, et al.
Publicado: (2020)

Immunohistochemical overexpression of BCL-2 protein predicts an inferior survival in patients with primary central nervous system diffuse large B-cell lymphoma
por: Chen, Yi, et al.
Publicado: (2019)

PB2294: DOSE-ADJUSTED EDOCH AS FIRST-LINE THERAPY IMPROVED PROGNOSIS OF ADULT T-CELL LEUKEMIA/LYMPHOMA: A 11-YEAR MULTICENTER RETROSPECTIVE STUDY IN CHINA
por: Luo, Luting, et al.
Publicado: (2023)

Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma
por: Yang, Haiyan, et al.
Publicado: (2022)

Prognostic nomogram incorporating inflammatory cytokines for overall survival in patients with aggressive non-Hodgkin's lymphoma
por: Zhong, Huijuan, et al.
Publicado: (2019)

Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma
por: Lee, Yong-Pyo, et al.
Publicado: (2021)

Management of relapsed-refractory diffuse large B cell lymphoma
por: Raut, Lalit S., et al.
Publicado: (2014)

Efficacy and safety of chimeric antigen receptor T cell therapy in relapsed/refractory diffuse large B-cell lymphoma with different HBV status: a retrospective study from a single center
por: Kong, Danqing, et al.
Publicado: (2023)

Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy
por: Argnani, Lisa, et al.
Publicado: (2022)

P1133: CHIDAMIDE PLUS PREDNISONE, CYCLOPHOSPHAMIDE, AND THALIDOMIDE (CPCT) FOR RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA: A MULTICENTER PHASE II TRIAL
por: Liang, Jinhua, et al.
Publicado: (2023)

Efficacy of salvage radiotherapy for relapsed/refractory diffuse large B-cell lymphoma
por: Wang, Shu-Bei, et al.
Publicado: (2019)

Real‐world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis
por: Yi, Jun Ho, et al.
Publicado: (2021)

Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition)
por: Chen, Suning, et al.
Publicado: (2022)

A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
por: Bachy, Emmanuel, et al.
Publicado: (2022)

S223: REAL-WORLD EARLY OUTCOMES OF AXICABTAGENE CILOLEUCEL FOR RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
por: Jacobson, Caron, et al.
Publicado: (2023)

Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Harris, Leonard Jeff, et al.
Publicado: (2020)

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Sehn, Laurie H., et al.
Publicado: (2020)

Limited efficacy of pixantrone in refractory diffuse large B-cell lymphoma
por: Novakovic, Aleksander, et al.
Publicado: (2020)

Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
por: Salles, Gilles, et al.
Publicado: (2021)

P1197: BRUTON’S TYROSINE KINASE INHIBITOR ZANUBRUTINIB IN RELAPSED/REFRACTORY PRIMARY DIFFUSE LARGE B-CELL LYMPHOMA OF CENTRAL NERVOUS SYSTEM: A PHASE II TRIAL
por: Wang, Yali, et al.
Publicado: (2023)

Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis
por: Sakkat, Abdullah, et al.
Publicado: (2022)

Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma
por: Li, Jiazheng, et al.
Publicado: (2021)

Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4)
por: Tao, Rong, et al.
Publicado: (2021)

Overall survival benefits provided by lenalidomide maintenance after chimeric antigen receptor T cell therapy in patients with refractory/relapsed diffuse large B-cell lymphoma
por: Ping, Nana, et al.
Publicado: (2022)

P1181: REAL-WORLD CHARACTERISTICS AND CLINICAL OUTCOMES IN RELAPSE/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA POST CAR-T FAILURE
por: Flores Avile, C., et al.
Publicado: (2022)

Mutated RAS-associating proteins and ERK activation in relapse/refractory diffuse large B cell lymphoma
por: Benoit, Alexandre, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8o3rcn7s9skq0jea1dts19v3rv